Project Grant R44TR004975
Award Date 9/25/25
Completion Date 8/31/27
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92617, USA
Similar Awards
- This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 provides $406,500.00 to Syntr Health Technologies, Inc. to develop an automated, microfluidic tissue dissociation platform called the SYNTRFUGE. This device aims to rapidly and efficiently process solid tumor tissue samples into single cells for diagnostic analysis and research, addressing a critical barrier to more widespread use of single-cell analysis in oncology. The...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $356,500.00 to Syntr Health Technologies, Inc. to accelerate the development of their SYNTRFUGE and SYNTRFPU360 tissue processing platform technology. This platform aims to enable large-volume tissue processing, including for tumor tissue analysis and adipose tissue for breast cancer reconstructive surgery and other regenerative medicine applications. The funds will support...
- The National Center for Advancing Translational Sciences (NCATS), through its CFDA 93.350 Federal Grant Program, awarded a $294,541 Project Grant to Cellular Vehicles Inc. on June 1, 2024. The purpose of this award is to develop an automated system for producing and delivering cell-laden hydrogel therapies. The project aims to create a novel, standardized process for formulating, encapsulating, and directly injecting cell-laden hydrogels into diseased tissues. This is intended to improve the...
- This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $329,272 to Capienda Biotech, LLC to develop a high-throughput kinetic system for small-molecule drug discovery. The goal is to create an innovative instrument that can rapidly characterize the binding kinetics of compounds targeting human cyclin-dependent kinases, which are important oncology targets. This will help medicinal chemists identify drug candidates...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...
- The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, awarded a $349,746 Project Grant to Cisterna Biologics, Inc., a biotechnology company based in Oceanside, California. The goal of this 1-year Phase I SBIR grant is to develop an innovative platform for synthesizing high-quality, purified mRNA with minimal contaminants such as double-stranded RNA, long RNA, and short truncated RNA. These impurities can provoke immune responses and...
- The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $1,077,369 Project Grant to Captis Diagnostics Inc. on March 11, 2025 to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system for the rapid, efficient, and cost-effective isolation of extracellular vesicles (EVs) from non-invasive bodily fluids. The project, funded under NCATS' Federal Grant Program (CFDA 93.350), aims to unlock the potential of EVs in multi-omics-based disease molecular characterization...
- The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
- This $305,352 Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) supports the development of a quantitative, home monitoring point-of-care test for determining total blood homocysteine (THCY) levels. The funding will allow Analytical Diagnostic Solutions Inc., a for-profit S corporation based in New Jersey, to create the "HCY NOW" device, which aims to significantly improve the management of homocystinurias (HCUs) - a group of...